Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABOUT γδ T Cells for Glioblastoma
NCT07144735Phase 1Recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Apr 2025
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial in glioblastoma multiforme (GBM) (3 arms), sponsored by Peking University Third Hospital. Primary endpoints: Incidence of Adverse Events at 3 months and Incidence of Dose-Limiting Toxicities at 28 days. Started Apr 2025; status: recruiting.
02
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT07144735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07144735.